Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,098 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evaluation of Vancomycin Dose Needed to Achieve 24-Hour Area Under the Concentration-Time Curve to Minimum Inhibitory Concentration Ratio Greater Than or Equal to 400 Using Pharmacometric Approaches in Pediatric Intensive Care Patients.
Jung D, Kishk OA, Bhutta AT, Cummings GE, El Sahly HM, Virk MK, Moffett BS, Morris Daniel JL, Watanabe A, Fishbane N, Kotloff KL, Gu K, Ghazaryan V, Gobburu JVS, Akcan-Arikan A, Campbell JD. Jung D, et al. Among authors: gu k. Crit Care Explor. 2024 Oct 1;6(10):e1159. doi: 10.1097/CCE.0000000000001159. eCollection 2024 Oct 1. Crit Care Explor. 2024. PMID: 39352409 Free PMC article.
Population Pharmacokinetics of Moxifloxacin in Children.
Greenberg RG, Landersdorfer CB, Rivera-Chaparro N, Harward M, Conrad T, Nakamura A, Kirkpatrick CM, Gu K, Ghazaryhan V, Osborn B, Walter EB. Greenberg RG, et al. Among authors: gu k. Paediatr Drugs. 2022 Mar;24(2):163-173. doi: 10.1007/s40272-022-00493-3. Epub 2022 Mar 14. Paediatr Drugs. 2022. PMID: 35284983 Free PMC article.
Evaluation of Empirical Dosing Regimens for Meropenem in Intensive Care Unit Patients Using Population Pharmacokinetic Modeling and Target Attainment Analysis.
An G, Creech CB, Wu N, Nation RL, Gu K, Nalbant D, Jimenez-Truque N, Fissell W, Rolsma S, Patel PC, Watanabe A, Fishbane N, Kirkpatrick CMJ, Landersdorfer CB, Winokur P. An G, et al. Among authors: gu k. Antimicrob Agents Chemother. 2023 Jan 24;67(1):e0131222. doi: 10.1128/aac.01312-22. Epub 2023 Jan 9. Antimicrob Agents Chemother. 2023. PMID: 36622154 Free PMC article.
Population pharmacokinetics and target attainment analyses to identify a rational empirical dosing strategy for cefepime in critically ill patients.
An G, Creech CB, Wu N, Nation RL, Gu K, Nalbant D, Jimenez-Truque N, Fissell W, Patel PC, Fishbane N, Watanabe A, Rolsma S, Kirkpatrick CMJ, Landersdorfer CB, Winokur P. An G, et al. Among authors: gu k. J Antimicrob Chemother. 2023 Jun 1;78(6):1460-1470. doi: 10.1093/jac/dkad106. J Antimicrob Chemother. 2023. PMID: 37071586 Free PMC article.
Population Pharmacokinetic Modeling of Cefepime, Meropenem, and Piperacillin-Tazobactam in Patients with Cystic Fibrosis.
Rolsma SL, Sokolow A, Patel PC, Sokolow K, Jimenez-Truque N, Fissell WH, Ryan V, Kirkpatrick CM, Nation RL, Gu K, Teresi M, Fishbane N, Kontos M, An G, Winokur P, Landersdorfer CB, Creech CB. Rolsma SL, et al. Among authors: gu k. J Infect Dis. 2024 Sep 30:jiae451. doi: 10.1093/infdis/jiae451. Online ahead of print. J Infect Dis. 2024. PMID: 39344185
Utilizing an Opportunistic Clinical Study and Population-Based Pharmacokinetic Models to Identify Rational Empiric Dosing Regimens for Piperacillin-Tazobactam in Critically Ill Patients.
Reeder JA, Creech CB, Nation RL, Gu K, Nalbant D, Wu N, Jimenez-Truque N, Fissell W, Rolsma SL, Fishbane N, Kirkpatrick CMJ, Patel PC, Watanabe A, Landersdorfer CB, Winokur P, An G. Reeder JA, et al. Among authors: gu k. J Clin Pharmacol. 2024 Dec 3. doi: 10.1002/jcph.6161. Online ahead of print. J Clin Pharmacol. 2024. PMID: 39628093
Pharmacokinetics of Ceftazidime-Avibactam in Combination with Aztreonam (COMBINE) in a Phase 1, Open-Label Study of Healthy Adults.
Lodise TP, O'Donnell JN, Balevic S, Liu X, Gu K, George J, Raja S, Guptill JT, Zaharoff S, Schwager N, Fowler VG Jr, Wall A, Wiegand K, Chambers HF; Antibacterial Resistance Leadership Group. Lodise TP, et al. Among authors: gu k. Antimicrob Agents Chemother. 2022 Dec 20;66(12):e0093622. doi: 10.1128/aac.00936-22. Epub 2022 Nov 17. Antimicrob Agents Chemother. 2022. PMID: 36394326 Free PMC article. Clinical Trial.
Population Pharmacokinetics of Piperacillin/Tazobactam Across the Adult Lifespan.
Hemmersbach-Miller M, Balevic SJ, Winokur PL, Landersdorfer CB, Gu K, Chan AW, Cohen-Wolkowiez M, Conrad T, An G, Kirkpatrick CMJ, Swamy GK, Walter EB, Schmader KE. Hemmersbach-Miller M, et al. Among authors: gu k. Clin Pharmacokinet. 2023 Jan;62(1):127-139. doi: 10.1007/s40262-022-01198-z. Epub 2023 Jan 12. Clin Pharmacokinet. 2023. PMID: 36633812 Free PMC article.
1,098 results